Filing Flows › Voyager Therapeutics (VYGR) › Q2 2026 › vs Q2 2025
Voyager Therapeutics (VYGR) Q2 2026 vs Q2 2025 (year over year)
Voyager Therapeutics's revenue fell $2.0M (-39%) from $5.2M in Q2 2025 to $3.2M in Q2 2026.
Voyager Therapeutics, Q2 2026: revenue $3.2M (-39% year over year), operating margin -833.9%, net loss $24.5M, operating cash flow −$25.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.2M | $5.2M | −$2.0M | -39% |
| Other income, net | $1.9M | $3.3M | −$1.3M | -40% |
| Net loss | $24.5M | $33.4M | −$8.9M | -27% |
| Costs & expenses | $29.6M | $41.8M | −$12.3M | -29% |
| Operating costs | $29.6M | $41.8M | −$12.3M | -29% |
| Income tax | $20K | $15K | $5K | +33% |
| Research & development | $22.0M | $31.3M | −$9.3M | -30% |
| General & admin | $7.5M | $10.5M | −$3.0M | -28% |
| Operating cash sources | $29.2M | $38.5M | −$9.3M | -24% |
| Depreciation | $908K | $1.1M | −$157K | -15% |
| Share-based compensation | $2.4M | $4.1M | −$1.7M | -41% |
| Cash used in operations | $25.8M | $33.3M | −$7.4M | -22% |
| Net loss absorbed | $24.5M | $33.4M | −$8.9M | -27% |
| Working capital & other | $4.7M | $5.1M | −$367K | -7% |
Questions
How much did Voyager Therapeutics's revenue grow year over year in Q2 2026?
Voyager Therapeutics's revenue fell $2.0M (-39%) from $5.2M in Q2 2025 to $3.2M in Q2 2026.